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Abstract
Background
Stereotactic ablative radiotherapy (SBRT) is a radical option for oligometastatic colorectal 
cancer (CRC) patients, but most data relate to visceral metastases.
Methods
A prospective, multi-centre database of CRC patients treated with SBRT was interrogated. 
Inclusion criteria were ECOG PS 0-2, ≤ 3 sites of disease, a disease free interval of > 6 months 
unless synchronous liver metastases. Primary endpoints were local control (LC), progression 
free survival (PFS) and overall survival (OS). 
Results
163 patients (172 metastases) were analysed. The median FU was 16 months (IQR 12.2 – 
22.85). The LC at 1 year was 83.8% (CI 76.4% - 91.9%) with a PFS of 55% (CI 47% - 64.7%) 
respectively. LC at 1 year was 90% (CI 83% - 99%) for nodal metastases (NM), 75% (63% - 
90%) for visceral metastases (VM). NM had improved median PFS (9 vs 19 months) [HR 0.6, 
CI 0.38 – 0.94, p = 0.032] and median OS (32 months vs not reached) [HR 0.28, CI 0.18 – 0.7, 
p = 0.0062] than VM, regardless of whether the NM were located inside or outside the pelvis. 
On multivariate analysis, NM and ECOG PS 0 were significant good prognostic factors. An 
exploratory analysis suggests KRAS WT is also a good prognostic factor.
Conclusion
Nodal site is an important prognostic determinant of SBRT that should incorporated into patient 
selection. We hypothesise this may have an immunoediting basis.
Introduction
Approximately 20% of colorectal cancer (CRC) patients present with stage IV disease [1]. Of 
those that present at an early stage and are treated radically, 20-30% will go on to develop 
metastatic disease [2,3]. Systemic therapy is the main treatment for metastases given the 
proven survival benefit, however metastasis directed therapy is increasingly being used to 
manage metastatic deposits in an attempt to achieve long term benefit [4]. Aggressive 
management of patients who have unresectable liver disease at the time of diagnosis [5] using 
radiofrequency ablation (RFA) has demonstrated an overall survival benefit versus standard 
of care [6]. The recent randomised phase II SABR-COMET trial demonstrated a survival 
benefit from the addition of stereotactic ablative body radiotherapy (SBRT) in 
oligometastatic disease at extra-cranial sites [7], where almost 20% of the patients had CRC. 
These data suggest that CRC patients can derive significant benefit in limited metastatic 
disease.
The oligometastatic state lies on a spectrum between localised and disseminated disease [8]. 
A concrete definition is lacking with the most common criteria being the number and location 
of radiologically identifiable metastases.  The ESMO consensus guidelines for the 
management of patients with metastatic colorectal cancer, defines oligometastases as five or 
sometimes more metastases at two or three sites, primarily visceral and lymph nodes [9]. 
Data from surgical cohorts in CRC demonstrate an improved 5-year OS for patients with 1-3 
resectable metastases, compared to 4-6, or more than 6, respectively [10], suggesting burden 
of disease is important. More recently there have been reports focusing on a specific primary 
cancer type or a specific treated metastatic site [11–15].
 
Visceral metastases (VM) are the most common metastases from CRC that are treated with 
SBRT[16] and much of the literature to date has focussed on either liver or lung metastases 
[17]. In the SABR-COMET trial [7] most patients had visceral metastases, while only 3 (6%) 
of metastases treated with SBRT were in lymph nodes. There are little data available on the 
outcomes of lymph node only oligometastases in colorectal cancer treated with SBRT. The 
treatment options for these patients are limited to systemic therapy, as RFA and surgery are 
less commonly performed, and there is some debate about whether or not the entire nodal 
chain should be treated. Furthermore, the mechanisms of spread for visceral and nodal 
oligometastases differ which may have implication for outcomes.
We analysed a prospectively collected, multicentre cohort of oligometastatic CRC patients 
treated with SBRT to identify differences in outcomes between treated visceral metastases 
(VM) and lymph node metastases (NM) at oligometastatic sites. 
Methods
Study population
Patients with CRC were identified from a prospectively collected register of patients [18] 
diagnosed with colorectal cancer treated across three UK sites (Oxford, Mount Vernon, 
Leeds). Key eligibility criteria were: confirmed histological diagnosis, ECOG PS 0-2, ≤ 3 
sites of disease and no more than 2 organ systems, no brain metastases, primary tumour 
resected with a disease free interval of > 6 months (synchronous presentations were permitted 
for liver metastases) as identified on multimodality imaging (CT, PET and MRI as 
appropriate), adequate organ function and no systemic treatment for 28 days or planned 
systemic treatment after SBRT. All nodes were confirmed as isolated through review of serial 
imaging. Patients with less than 3 months of follow were excluded. All metastatic lesions 
were treated, where there was more than one. All patients consented to collection of data as 
part of enrolment in the SBRT treatment program which had received ethical approval (North 
East – York Research Ethics Committee REC reference: 16_NE_0285).
Techniques of radiotherapy
All patients were scanned with helical CT using ≤5mm interval. Gross tumour volume (GTV) 
was outlined and clinical target volume (CTV) was equal to GTV for all lesions except liver 
metastases where, a 5 mm margin in all directions was applied added to GTV to define CTV. 
Radiotherapy planning CT images were co-registered with diagnostic radiology at the 
treating oncologist’s discretion. Where disease sites were subject to internal movement (such 
as lung or liver), patients were planned using 4D-CT scan. Abdominal compression or 
fiducial tracking [19] was used for abdominal motion management. A margin of 3-5 mm, 
depending on disease site and dimensions, was added to GTV/ CTV to obtain the planning 
target volume (PTV). Details of radiation doses, which varied according to tumour sites, are 
provided in Supplementary Table 1. An α/β ratio of 10 was used for biologically effective 
dose (BED) calculations. KRAS mutation status of the primary tumour was collected by 
retrospective review of pathology reports. All mutations were activating driver mutations and 
detected by next generation sequencing of the primary tumour using a targeted gene panel.  
Response assessment
First evaluation was planned 3 months after the end of the SBRT and then every 3 months for 
the first year and every 6 months from the second to the fifth year. Follow-up visits included 
clinical evaluation and diagnostic imaging (CT, MRI or PET scan) at treating physician’s 
discretion. End points of the present study were local control (LC), defined as absence of 
progression inside the SBRT treated volume; locoregional progression (LRP), defined as 
progression outside the treated volume in an adjacent nodal station/chain or within the same 
organ (liver/lung) and distant progression (DP), as metastasis within another organ system or 
anatomically remote from the treated lesion. Toxicity data was collected as part of the overall 
treatment program and is publically available [20].
Statistical analysis
All outcomes were calculated from date of SBRT treatment. Time to any progression (LC / 
LRP / DP) was defined as PFS and overall survival (OS) treatment to either death or 
censoring. Univariate analysis was performed with the log-rank test, and Cox proportional 
hazards regression was used to estimate hazard ratios (HR). The primary endpoints were PFS 
and OS. Multivariable stepwise cox regression analysis was performed to evaluate the 
association between clinical factors and survival, with a significance level of p < 0.05. 
Survival analysis was performed using Cox regression models and Kaplan Meier estimates 
with log rank testing. Median follow-up was ascertained by reverse-censoring method. 
Patients without the event of interest were censored at the time last known to be event-free. 
All statistical analysis was performed using R statistical software [21]. 
Results
A total of 184 patients were treated between September 2015 and October 2018. Nine were 
excluded as the treated site was intracranial and 12 excluded due to inadequate or missing 
follow up. The final cohort was 163 patients with 172 treated lesions. The median follow up 
was 16 months (IQR 12.2 – 22.85). The cohort characteristics are summarised in Table 1. 
Toxicity was consistent with published series and is available elsewhere, with no deaths due 
to SBRT [20]. The median BED10 for the all sites was 79.2Gy.  All lesions received the 
prescribed dose. Only 23% of patients had not received prior systemic therapy prior to SBRT. 
KRAS mutation status was available for 64 (39%) of patients. 
The 1 and 2 year local control rate for the whole cohort was 83.8% (CI 76.4% - 91.9%) and 
77.4% (CI 67.9% - 88.2%) respectively. However, the 1 year local control rate varied 
significantly different according to treated site; 58% for liver (36.7% - 92.7%), 90% for 
lymph nodes (82.9% - 99%) and 92% for lung (80.3% - 100%).
In total, 86 patients with 95 lymph nodes metastases were treated. These were mapped to four 
anatomical locations: mediastinum, upper abdomen, para-aortic nodes and pelvic/inguinal 
nodes [Figure 1]. 53 out of 95 (56%) of nodes never progressed. Of the remaining 42, only 2 
progressed in-field and 12/42 (28%) progressed at multiple sites. 
At 1 year and 2 years respectively, PFS for the whole cohort was 55% (CI 47% - 64.7%) and 
37.6% (CI 29% - 48.8%) while OS was 93% (88.6% - 98%) and 74% (CI 64.5% - 85.4%).  
Median PFS for the whole cohort was 13.9 months, with median OS not reached. VM (liver, 
lung & bone) had a worse median PFS (9 months vs 19 months) and worse median OS (32 
months vs not reached) than nodal metastatic sites, reflected in a statistically significant 
difference by Cox regression for PFS [HR 0.6, 95% 0.38 – 0.94, p = 0.032] and OS [HR 0.28, 
95% 0.18 – 0.7, p = 0.0062] [Figure 2]. On univariate analysis there was no significant in 
PFS difference for ECOG PS, primary site or synchronous/metachronous disease at 
presentation (Table 2). Patients in receipt of chemotherapy (adjuvant or metastatic) prior to 
SBRT had an increased hazard for progression [HR 1.93, C.I 1.08 – 3.45; p = 0.027]. On 
univariate analysis for OS, ECOG PS 1 or 2 were associated with an increased risk of death, 
relative to PS 0, but only the former was statistically significant with an overall low number 
(5) of PS 2 patients [Table 2]. Patients who had previously received systemic chemotherapy 
prior to SBRT had an increased hazard for progression [HR 1.93, CI 1.08 – 3.45; p = 0.027] 
and increased hazard for death, with a trend towards statistical significance.
 
Significant factors on univariate testing were included in a multivariate analysis for PFS and 
OS [Table 3], where VM remained significantly associated with poor outcomes. Inclusion of 
local control in a OS multivariate cox model showed that poor local control and an ECOG PS 
1/2 were significantly associated with worse overall survival (Supplementary Table 2). NM 
site was associated with an improved OS outcome [HR 0.37, CI 0.14 – 0.95, p = 0.038]. 
To understand if the improved outcomes of NM was due to the large proportion of pelvic LN 
(50%), these were compared to distant, extra-pelvic NM sites and VM. On Cox regression 
analysis, relative to extra-pelvic LN, VM had an inferior PFS [HR 2.24, C.I 1.23 – 4.17; p = 
0.008] and inferior OS [13.9, C.I 1.85 – 105.6; p = 0.01] but pelvic LN did not have 
significantly worse PFS [HR 1.86, C.I 0.94 – 3.68; p = 0.074] or OS [HR 8.15, C.I 0.97 – 
67.85; p = 0.052] [Figure 3].
The effect of KRAS mutation status was explored in the subgroup of patients for whom 
mutation testing of the primary tumour was available (N=64), 30% of which were KRAS 
mutant. Other activating mutations, such as BRAF, were less common as expected [22], and 
not detected in sufficient numbers for analysis. There was no significant difference in the 
distribution of oligometastatic sites (liver, node, lung, bone) by KRAS mutation (Fisher’s 
exact test, p = 0.346). There was no difference in local control rates between KRAS wild type 
and mutant cases (log rank p = 0.63) [Figure 4A]. KRAS wild type was associated with 
improved PFS [HR 0.42, 95% CI 0.2 – 0.87; p = 0.02] and OS [HR 0.2, 95% CI 0.05 – 0.76; 
p = 0.02] [Supplementary Figure 1]. The median PFS for wild type was 13 months versus 7 
for mutant patients. On multivariate Cox regression analysis, nodal metastases and KRAS 
wild type remained significant prognostic factors [Nodal HR 0.09, 95% CI 0.02 – 0.4, p = 
0.002; KRAS wild type HR 0.1, 95% 0.01 – 0.5, p = 0.007].  
Discussion
In this prospectively collected, multicentre cohort study we showed patients having SBRT for 
nodal oligometastases enjoy better survival outcomes, relative to those treated for visceral 
metastases. The cohort was accrued over a short period of time (3 years) and had a LC at 1 
and 2 years of 83.8% and 77.4%, respectively. LC in liver metastases appeared to be worse 
compared to other sites within the cohort and consistent with a systematic review of SBRT in 
CRC [23], which estimated wide variation local control rates for liver metastases of between 
50%-100% at 1-year and 32%-91% at 2 years. Previous data had suggested that CRC patients 
with oligometastatic disease to liver have worse outcomes compared to other disease types 
treated with SBRT [13,24]. Radiosensitivity among liver metastases from CRC is 
heterogeneous compared to other sites[25] and this may account for the varying local controls 
rates [23].
A recent large single-centre CRC demonstrated 1-year local control of 95% and 3-year rate of 
>70% for the whole cohort [11]. Although there was no difference in LC between lung vs 
non-lung metastases, they did not present the LC rates by site and had low numbers of nodal 
sites (12.4%). Factors which negatively influenced OS in multivariate analysis were non-lung 
sites [HR 1.97 (1.30–2.99), p = 0.02], CTV >30mm [HR 1.73 (1.18–2.55), p = 0.03], 
systemic therapy before SBRT [HR 1.61 (1.01–2.57), p =0.023] and poor local control [HR 
1.59 (1.04–2.43), p=0.007]. Similar findings had been reported in a multi – tumour cohort 
where prior systemic therapy resulted in worse LC [13]. A consistent interpretation is that 
achieving good local control of treated sites can lead to improved survival outcomes. 
Although local control, strictly speaking, is an outcome variable as opposed to pre-treatment 
variable, and thus has no use in selecting patients for SBRT, such analyses are common in 
SBRT cohorts. It should be noted however that assessment of local control could vary 
between reporting radiologists in a multi-institutional study, imaging modalities and 
anatomical sites, particularly liver lesions. Even though all participating centres and high 
volume, experienced, accredited SBRT institutions this is a potential weakness in our LC 
estimates. 
The majority (56%) of nodal metastases never progressed in field during follow up. Of the 42 
that did progress, 12 patients had LRP only and 28% had LRP and multi-site progression 
while 38% had distant disease. The pattern of relapse post SBRT justifies considering local 
tumoricidal treatments only to isolated nodal disease. Introduction of CTV around NM may 
decrease LRP but would increase toxicity. The excellent local control achieved with SBRT in 
nodal disease translated into an improved time to progression (19 vs 9 months) and sustained 
into an OS benefit. Conversely, worse local control as seen in the liver metastases, was 
associated with worse OS in the multivariate analysis [HR 3.3 (95% CI 1.35 – 8.78), p = 
0.016]. Given that 50% of visceral metastases had progressed by 9 months suggests that in 
such patients SBRT and systemic therapy could be better therapeutic approach, analogous to 
liver resections.
KRAS mutation has recently been shown to be a prognostic biomarker of worse survival 
outcomes in metastatic colorectal cancer in a large meta-analysis of first line randomised 
chemotherapy trials [26], an analogous situation to those referred for SBRT. Kinj et al found 
that KRAS mutation was associated with inferior metastasis free survival, but not OS, 
following SBRT in lung metastases [14] . In a randomised phase II trial of proton therapy for 
liver metastases KRAS mutants and TP53 mutants had worse local control than wild type 
patients [24]. A recent comprehensive study of tumour mutation status in a multisite cohort 
[27] demonstrated similar findings. Interestingly, although only 10% of their cohort, NM had 
100% LC at 2 years. We suggest that KRAS mutation is a relevant prognostic factor in 
oligometastatic CRC and be incorporated as a stratifying factor into future SBRT studies.
Our study has limitations. Our median follow up is shorter than some published datasets 
[11,28,29], but not all [30], in part due to data collection permissions. However, the 
significant majority of relapse events after surgery occur in the first 2-3 years [2]. Our cohort 
had already accrued 6 months DFS prior to entry in the SBRT program, in addition to the 
median follow up which was calculated from date of SBRT. Our cohort represents a very 
clear subset of the recent ESTRO/EORTC OMD classifier [31] – metastatic oligorecurrence – 
which represents 83% [Table 1] and should be interpreted as such. We did not have 
histological and molecular mutation confirmation of every treated site and thus inferred 
KRAS status. KRAS status of the primary tumour shows high concordance with mutation 
status in tissue sampled from metastases [32–34] however. Given the small sample numbers 
of known KRAS patients, the analysis could be subject overfitting in MVA and is hypothesis 
generating. 
Although a variety of radiotherapy doses were used, leading to range of BED, each site was 
treated consistently with the same dose. The schedules used are equivalent to those mandated 
in the SABR-COMET trial [7]. BEDmax has previously been attributed to improved LC in 
liver metastases [12,13]. An analysis of dose effect on outcomes is not possible as it is 
confounded by treated site.  Here, NM had the best LC despite the lowest prescription dose 
(BED10 60-93.3Gy) suggesting more fundamental biological differences in radiation response 
between sites. 
One potential working hypothesis for the observed differences are different routes of spread, 
with visceral metastases spreading haematologically and nodal metastases through the 
lymphatic system. The ability of the immune system to influence a cancer’s clinical course - 
“cancer immunoediting” - is marked by three distinct phases: elimination, equilibrium, and 
escape [35]. The clinical existence of oligometastases suggests that these tumours have 
escaped cancer immunoediting. LN are historically viewed as production sites for antigen-
specific (adaptive) effector cells but they also contain a spatially co-ordinated diverse 
multicellular network of lymphoid cells (innate) that can rapidly generate a cytokine response 
[36]. Radiotherapy engages both the adaptive and innate immune system to convert the 
irradiated tumour into an ‘in-situ vaccine’ that elicits a tumour specific T-cell response [37]. 
In doing so, radiotherapy can assist recalibration of the immunoediting process, switching 
escape back to elimination and equilibrium. Once ‘vaccinated’ an individual may have the 
immune memory capacity to prevent (elimination) or defer (equilibrium) the development of 
synchronous disease sites. 
In support of this theory, a recent study by Pitroda et al, of integrated molecular analysis of 
CRC metastases, an immune enriched subtype developed limited numbers of clinically 
evident synchronous metastases and was associated with improved survival outcomes [38].  
These data would be consistent with the immunoediting hypothesis. Furthermore, they 
demonstrated that increased KRAS signalling was associated with worse survival outcomes, 
consistent with our data.
Treatment options for metastatic CRC are slow to progress compared to other common 
cancers, with cytotoxic chemotherapy still the mainstay of treatment. SBRT is an excellent 
tool that offers a radical, potentially curative, option to patients with limited disease spread. 
However, optimum selection of patients and sequencing of therapies to maximise benefit has 
yet to be clarified. The current study represents an important step forward in highlighting the 
need for biological selection of patients for SBRT, in addition to known clinical factors. A 
better understanding of the local and circulating immune response generated by SBRT is 
needed to fully explain the varying outcomes seen in this and other studies of oligometastatic 
CRC. 
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Figures Legend
Figure 1. Body diagram showing the anatomical sites of metastases with an associated count 
grid indicating the outcome (distant progression [DP], in field progression [IFP], locoregional 
progression [LRP]). 
Figure 2. Kaplan Meier plots with associated risk tables of progression free survival (A) and 
overall survival (B) outcomes for visceral (red) and nodal (blue) metastases
Figure 3. Kaplan Meier plots with associated risk tables of progression free survival (A) and 
overall survival (B) outcomes for pelvic NM, distant NM (outside the pelvis) and visceral 
metastases
Supplementary Figure 1. Kaplan Meier plots for clinical outcomes of KRAS wild type 
compared to KRAS mutant tumours [N=64]. There was no difference in local control (A). 
Progression free survival (B) and overall survival (C) were significantly improved for KRAS 
wild type patients with a median difference of 4 months and 17 months respectively
Highlights
 SBRT for CRC results in excellent local control rates for nodal metastases
 Median PFS for NM was 19 months versus 9 months for VM
 Nodal site was significant prognostic factor on multivariate analysis for PFS/OS
 We hypothesise an immunoediting basis for the improved outcomes of NM 
Table 1. Cohort characteristics
Variable N = 163 %
Age 69 
(Range 36-91)
Gender
Male 90 55
Female 73 45
ECOG
0 99 61
1 52 32
2 5 3
Unknown 7 4
Primary site
Rectum 81 50
Colon 82 50
Treated site
Liver 38 23
Lymph Node 86 53
Lung 34 21
Other* 5 3
Median BED 10 
(across all sites)
79.2 Gy 
(IQR 48 – 105)
KRAS status
Wild type 45 28
Mutant 19 12
Not tested 99 61
GTV 9.725 cm3 
(Range 2.03 – 39.2)
Metachronous 135 83
Synchronous 28 17
Lines of 
chemotherapy
0 38 23
1 86 53
2 34 21
3 2 1
Number of 
metastasesǂ
1 151 93
2 10 6
3 2 1
* Tail of pancreas, left flank, pancreas bed, spine and penile bulb
ǂ >1 metastases treated as a single GTV are considered as isolated metastases. 
Table 2. Univariate analysis for Local Control, Progression Free Survival and Overall Survival
LC PFS OS
Variable HR (CI) p value HR 
(CI)
p value HR (CI) p value
ECOG PS
0 Reference
1 1.11 
(0.43 – 2.86)
0.831 1.02 
(0.63 – 1.65)
0.932 2.75 
(1.13 – 6.68)
0.025*
2 2.28 
(0.29 – 17.75)
0.43 0.51 
(0.07– 3.71)
0.506 4.85 
(0.6 – 39.14)
0.138
Primary site
Rectum
(ref Colon)
0.88
(0.37 – 2.12)
0.779 1.0
(0.64 – 1.55)
0.984 0.7
(0.31 -1.57)
0.382
Prior chemotherapy
(ref no chemotherapy)
1.71
(0.57 – 5.15)
0.337 1.93 
(1.08 – 3.45)
0.027* 3.18 
(0.94 -10.72)
0.063
Synchronous 
presentation
(ref metachronous)
0.88
(0.26 – 3.02)
0.842 1.61 
(0.96 – 2.71)
0.070 1.32 
(0.49 – 3.55)
0.579
Lymph node site
(ref visceral site)
0.6
(0.25 – 1.46)
0.262 0.61 
(0.39 – 0.96)
0.032* 0.29 
(0.12 – 0.7)
0.006*
* denotes statistically significant at the 0.05 level
